DV
Dividend Vision

GRCL — Gracell Biotechnologies Inc.

Gracell Biotechnologies Inc. (GRCL)

Total return is 1915.2% over the past 5.6 years, 1795.9 points ahead of SPY at 119.3%. Its deepest 1-year drawdown was 27.3%.

GRCL is a single-stock equity holding in Gracell Biotechnologies Inc., a biotechnology company, rather than a diversified ETF fund. The holding does not currently pay dividends, resulting in no yield or distribution frequency. With limited publicly available fund data including expense ratio and assets under management, this appears to be a specialized equity position suited primarily for investors seeking direct exposure to the biotechnology sector's growth potential rather than income generation.

GRCL key facts

Asset type
Stock
Asset class
Equity
Inception date
01/08/2021
Last close
$505.00
Market cap
$989,867,072
Average volume
1500.0
Beta
-0.345
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.97